Track topics on Twitter Track topics that are important to you
South Korean firm Celltrion Healthcare is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar, Remsima (infliximab), which was rolled out across Europe ...
South Korea's Celltrion and Samsung Bioepis are competing hard to grab a slice of the burgeoning global biosimilar market. Celltrion’s Remicade biosimilar has already been widely launched and may on...
"Further percolation will not advance the law," Hospira and Celltrion said, insisting that "settling the issue will spur competition."
South Korean biotechnology company Celltrion has, according to Business Korea, submitted a second biosimilar application to the European Medicines Agency (EMA).
Korean biopharmaceutical company Celltrion is to start using cloud-based technology to accelerate development…
Korean drugmaker Celltrion filed for approval from the European Medicines Agency for CT-P10, a biosimilar for the monoclonal -More-
Celltrion contends that since it provided its infliximab biosimilar application to Janssen it doesn’t have to wait until FDA approval to provide 180-day notice of commercial launch.
Celltrion Inc. (KOSDAQ:068270) filed an inter partes review (IPR) petition with the U.S. Patent and Trademark Office challenging a patent from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) t...